

# AGENDA

## Board Meeting November 29, 2024, 9:00am-10:00am

Location: Online Zoom Meeting

To attend via Zoom webinar, please register at this link:

https://nhvaccine.org/event/nhva-november-20-2024/

Time	Agenda Item
9:00-9:05	1. Welcome & Roll Call (Tenney)
	a. Roll Call
	b. Board Chair Statement re: Public Commentary During Meetings*
9:05-9:10	2. Review and Acceptance of Minutes (Tenney)
	a. September 18, 2024 Board Meeting Minutes – <b>VOTE*</b>
9:10-9:20	3. Review and Acceptance of FY2024 Annual Report (Tenney)
	a. FY2024 Annual Report – <b>VOTE*</b>
9:20-9:30	4. Executive Director Report (Miller)
	a. Review of FYTD 2025 Unaudited Financial Statements*
	b. Financial Auditor RFP
9:30-9:40	5. DHHS Update (Mercuri)
9:40-9:50	6. Public Comment if Time Permits
9:50-10:00	7. Executive Session – Board Attendance Only
10:00	8. Adjournment

\* Indicates an attachment.

# NEW HAMPSHIRE VACCINE ASSOCIATION Board Chair Statement re: Public Commentary During Meetings

I welcome members of the public. Please also inform the Board now if you will be recording this meeting by raising your hand or using the chat feature.

If the Board has sufficient time to conduct its business, then it is our policy to reserve time later in the meeting for public commentary. This commentary should be limited to matters that are germane to the role of the NH Vaccine Association: namely, the assertion and collection of assessments to fund the non-federal portion of the State's purchase and distribution of vaccines under the federal Vaccines for Children program. The Vaccine Association is not a policy-setting organization, it has no influence over the State's participation in the Vaccines for Children Program, and its role is not to challenge the vaccine program cost estimates provided by the State absent obvious error. Therefore, as Chair of the Board, I reserve the right to interrupt and end any public commentary that is not germane to the business of this Association.

Lastly, I remind the public that the commentary period is not an interactive session. If you have questions for the Board or for its executive staff, please direct them to our Executive Director who will respond in the normal course of Association business.

Thank you in advance for adhering to these public commentary guidelines so that we may have a productive meeting.



1 2 3 4 5 6 7	MINUTES Board of Directors Meeting September 18, 2024 Scheduled 9:00 a.m. – 11:00 a.m. Presiding Officer: Susan Tenney, Chair The meeting of the Board of Directors of the New Hampshire Vaccine Association (NHVA) was held via Zoom Webinar											
, 8 9	with a quorum present. The meeting was called to orde											
10 11	Attendance – The following individuals attended the m	eeting:										
	Board Members:	Members of the Public										
	Susan Tenney, HPHC, Chair Jason Margus, Anthem, Treasurer Marc Fournier, USNH, Self-Insured Entity Robert Dimauro, Cigna, Proxy for Morgan Brown Michelle Heaton, NHID Jerry Knirk, MD, Public Member Anne Marie Mercuri, NH DHHS <b>Excused Board Members:</b> Edward Moran, Public Member, Vice Chair Morgan Brown, Cigna, Secretary Patricia Edwards, MD, Healthcare Provider Wendy Wright, DNP, Healthcare Provider <b>Administrative Staff &amp; Invited Guests:</b> Patrick Miller, Helms & Company, Inc.	Brooke Cardoso, CSL Seqirus Laura Condon, Bedford, NH Luke Cunniff, Merck Brittany DeBernardo Jason Gerhard, Belmont, NH James Higginbottom, Rochester, NH Diane Kelley, Temple, NH Jenny Lind, Dover, NH Elizabeth Manley, Sanofi NH Representative Tom Mannion, Pelham, NH Lisa Mathews, Keene, NH Nikki McCarter, Belmont, NH NH Representative Kristin Nobel, Bedford, NH NH Representative Emily Phillips, Fremont, NH										
	Fatrick Miller, Heims & Company, Inc. Erin Meagher, Helms & Company, Inc. Keith Nix, Helms & Company, Inc. Mark McCue, Esq., Hinckley Allen Karen Carew, Carew & Wells, PLLC Leslie Walker, Mason+Rich, PA	NH Representative Emily Philips, Fremont, NH NH Representative Yury Polozov, Hooksett, NH Andrew Rennekamp, CSL Seqirus Jeff Russo, Wolfeboro, NH Larisa Trexler, Stoddard, NH										
12 13 14 15	1. Welcome and Roll Call Ms. Tenney welcomed everyone to the Board of Direct.	ors meetings of the NH Vaccine Association. She asked if any										

Ms. Tenney welcomed everyone to the Board of Directors meetings of the NH Vaccine Association. She asked if any members of the public were recording the meeting to please indicate so by raising their virtual hand. Ms. Condon indicated she was recording. Ms. Tenney conducted a roll call of Board Members for attendance at the Annual

18 Meeting of Members:

19				
20		<u>Present</u>	<u>Excused</u>	
21	Robert Dimauro	Х		
22	Patricia Edwards, MD		Х	
23	Marc Fournier	Х		
24	Michelle Heaton	Х		
25	Jerry Knirk, MD	Х		
26	Jason Margus	Х		
27	Anne Marie Mercuri	Х		
28	Edward Moran		Х	
29	Susan Tenney	Х		
30	Wendy Wright, DNP		Х	



31 Ms. Tenney subsequently read the "Board Chair Statement re: Public Commentary During Meetings."

32

Ms. Tenney then announced that Ms. Radick had resigned from the Board of Directors for personal reasons and
 thanked her for her service over the years. She then welcomed Dr. Knirk to the Board, as a representative appointed
 by the NH Senate President, and asked him to provide a brief history of his experience.

36

# 37 2. Executive Session with Karen Carew of Carew & Wells, PLLC

38

47

49

80

39 Ms. Tenney invited Ms. Carew to present the draft financial statements for fiscal years ending June 30, 2024 and 40 2023. She began with a review of the governance letter. There was one adjustment that occurs annually related to 41 accrued legal expenses that is considered immaterial. She stated there was no management letter issued this year 42 as there were no recommendations for the Administrator (Helms). Ms. Carew stated that the draft financial 43 statements for fiscal years ending June 30, 2024 and 2023 were considered to have a clean opinion and that the 44 process was smooth with full cooperation from the Administrator's staff. She noted that the total assets were down 45 slightly, but that the organization had funds to meet its obligations. She asked the Committee members if they had 46 any questions. There were none.

48 Ms. Tenney asked for a motion to move into an Executive Session with Ms. Carew.

Jason Margus

50	, 5, , , , , , , , , , , , , , , , , ,											
51 52	VOTEL		session at	9:14 a.m	. With Mis. Carew for further discussion							
52 53		of the FY2024 audit.										
55 54			Vac	No	Eveneed							
55		Robert Dimauro	<u>Yes</u> X	<u>No</u>	Excused							
56		Patricia Edwards, MD	^		x							
57		Marc Fournier	x									
58		Michelle Heaton	X									
59		Jerry Knirk, MD	x									
60		Jason Margus	x									
61		Anne Marie Mercuri	X									
62		Edward Moran			X							
63		Susan Tenney	x									
64		Wendy Wright, DNP			X							
65												
66	Ms. Mercuri was unable	e to join the Executive Session due	to techn	ical diffic	ulties. Since she had been part of the							
67	Audit Committee's revie	w of the audit, Ms. Mercuri did not	have any	, questior	ns for Ms. Carew.							
68												
69	Returning from the Exec	utive Session at 9:23 a.m., Ms. Ten	ney asked	d for a mo	otion.							
70												
71	VOTE RECORDED:	-	-	-	us, by roll call it was unanimously							
72	VOTEL	D: To accept the FY2024 A	udit as pr	esented b	y Carew & Wells.							
73												
74			<u>Yes</u> X	<u>No</u>	<u>Excused</u>							
75		Robert Dimauro	X									
76		Patricia Edwards, MD			X							
77		Marc Fournier	X									
78		Michelle Heaton	X									
79		Jerry Knirk, MD	Х									

Х



81			Anne Marie Mercuri	X	×.	
82			Edward Moran	N.	X	
83			Susan Tenney	X	X	
84 85			Wendy Wright, DNP		X	
85 86 87	3. Rev	view and Accepta	nce of the June 12, 2024, Bo	ard of Director	s Meeting Minutes	S
88	Ms. Ter	nney asked if there	was any discussion or chan	ges necessary r	egarding the June	12, 2024, Board of Directors
89			o suggested changes, Ms. Te			
90		-		-		
91	VOTE R	ECORDED:	On a motion by Ms. Heaton	, seconded by I	Mr. Fournier, by rol	ll call it was unanimously
92		VOTED:	To approve the Jur	ne 12, 2024, Bo	ard of Directors me	eeting minutes as presented.
93						
94				Yes	<u>No</u> <u>Excused</u>	<u>d</u>
95			Robert Dimauro	x		
96			Patricia Edwards, MD		X	
97			Marc Fournier	X		
98			Michelle Heaton	X		
99			Jerry Knirk, MD		Abstain	
100			Jason Margus	X		
101			Anne Marie Mercuri	x		
102			Edward Moran		X	
103			Susan Tenney	X		
104			Wendy Wright, DNP		X	
105						
106	4. Exe	ecutive Director R	eport – Guest, Leslie Walker	, Mason+Rich,	PA	
107						
108	Ms. Ter	nney invited Mr. M	liller to provide the Executive	e Director repo	rt.	
109						
110	a. Re	view and Accepta	nce of CY2025 Rate Setting			
111						
112	Mr. Mi	ller began by tha	nking the Audit Committee	members, Ms	. Walker, and Mr.	. Nix for their assistance in
113						esigned to assist the Board
114						ell as the core assumptions
115	underly	ving the model. The	ere was an Audit Committee	meeting on Au	ugust 21 <sup>st</sup> and anot	her on September 5 <sup>th</sup> where
116	differer	nt rate assumption	ns and rates were considere	ed. Ultimately,	the Audit Commit	ttee recommended that the
117	CY2025	assessment rate b	pe increased by twenty-five o	ents per cover	ed child life from tl	he CY2024 rate to \$12.75.
118						
119	In the A	August meeting, t	he Audit Committee wanted	l to see additio	onal modeling opti	ions that would cover three
120	points:					
121	-	Would like RSV r	irsevimab costs absorbed in	CY2025 rate w	ithout an additiona	al, one-time assessment.
122	-		25 rate to remain at CY2024	· ·		
123	-	Would like to en	sure that reserve targets are	met in CY2026	and CY2027.	
124						
125					<b>.</b> .	A for childhood vaccines, of
126						nds. For CY2025 rate setting,
127	-	•	•	ered lives, the	inclusion of nirse	vimab given the passage of
128	SB559,	and strengthening	the reserves.			



Mr. Miller proceeded to review the historical trends: assessment rates, covered lives, CDC weighted price increases,
 specific immunization cost increases, fund source split, cash and investments, unemployment rates, and NH
 Medicaid enrollment.

133

Mr. Miller then reviewed the data provided by the NH DHHS related to prior expenditures, projected cost estimates, and administrative costs. Mr. Miller stated that the NH DHHS estimates costs will be \$2.1M greater than last fiscal year due to increased childhood population, increased cost of vaccine, new immunizations, and maintaining the CDC balance. To manage costs, NH DHHS reduced the pre-book influenza amounts by 5,000 doses and is conservatively ordering nirsevimab and COVID-19 immunizations.

139

Mr. Miller then reviewed each of the rate modeling components used in the NHVA assessment rate modeling tool. He provided an overview of why reserves are necessary given the recent introduction of high-volume high-cost immunizations and continued expectation of this trend. He further provided information regarding the due dates by calendar year of the laddered CD portfolio as this is part of the cash management strategy under consideration during the assessment setting process.

Mr. Margus commented that the Audit Committee discussed the difference scenarios and felt the slight increase of twenty-five cents would be an acceptable pricing increase for insurance carriers and that incremental increases were better than a large increase all at once. Ms. Tenney concurred, stating this kept assessment rates more predictable for insurance carriers.

150

152

145

151 Ms. Tenney asked for a motion on the proposed assessment rate.

153 VOTE RECORDED: On a motion by Mr. Margus, seconded by Mr. Fournier, by roll call it was unanimously
 154 VOTED: To approve the proposed CY2025 assessment rate of \$12.75 per covered child life
 156 per month.

156				
157		<u>Yes</u>	No	<u>Excused</u>
158	Robert Dimauro	X		
159	Patricia Edwards, MD			X
160	Marc Fournier	X		
161	Michelle Heaton			X (exited meeting at 9:30 a.m.)
162	Jerry Knirk, MD	x		
163	Jason Margus	Х		
164	Anne Marie Mercuri	Х		
165	Edward Moran			X
166	Susan Tenney	Х		
167	Wendy Wright, DNP			X
168				

# 169 b. Review of FYTD 2025 Unaudited Financial Statements

Mr. Miller reviewed the FYTD 2025 unaudited financial statements. He began by saying that the August 15, 2024,
assessment revenue total was \$98,000 ahead of budget. The statements have accrued \$23,760,041 for the July 2025
payment to the State, based upon Tab C in the annual NH DHHS request. That number will change (plus or minus)
as actual vaccine expenses are accrued in the fiscal year. In terms of total assets, as of August 31, the organization
had \$12.2M in cash and investments. Finally, the administrative budget as of August 31, is \$1,381 ahead of budget.
Mr. Miller stated that there is nothing remarkable to report in the financial statements.

177

170

178 c. Preliminary CY2025 Meeting Schedule

179



180 181 182			-			gainst Ms. Tenney's and Mr. Margus' olds for the CY2025 meetings.								
183 184	5. NH	Department of H	lealth and Human Services (N	IH DHHS) Upd	ate									
185 186	Ms. Ter	nney asked Ms. M	ercuri to provide the NH DHH	S update. Ms.	Mercuri	provided the following updates:								
187	DHHS S	FY2025 increased	program cost estimates are b	ased upon sev	veral fact	ors:								
188	-	Increased child			2									
189	-	Increased cost o	f vaccine (3%)											
190	-		ons: i.e., nirsevimab											
191	-	Increased CDC b	alance.											
192														
193	The SFY	25 NHVA expendi	itures to date are \$4,920,354.											
194														
195	DHHS p	rogram cost conti	rols include:											
196	-	Reduced the nu	mber of pre-booked influenza	doses by 5,00	00									
197	-	Conservative or	dering of nirsevimab and CO	VID-19, replac	ing inve	ntory as needed (similarly as to other								
198		routine vaccinat	ions)											
199	-	Waste reductior	achieving historically low lev	els of waste.										
200														
201	6. Pu	blic Comment <sup>1</sup>												
202														
203	Ms. Ter	nney asked if any i	members of the public would	like to offer co	omments	. Ms. Condon stated:								
204	1.	That mRNA vacc	ines are not covered under th	ne NHVA's stat	utory de	finition of vaccine.								
205	2.	There is no state	ement in the financial stateme	ents or a 990 r	egarding	lobby costs for SB559.								
206	3.	That tracking ma	arket pricing versus CDC's man	nufacturer list	pricing v	vould be more accurate.								
207														
208	7. Exe	ecutive Session												
209														
210	Ms. Ter	nney asked for a m	notion to move into Executive	Session.										
211														
212	VOTE R	ECORDED:	-			rnier, by roll call it was unanimously								
213		VOTED	: To move to Executi	ve Session at 2	10:07 a.n	1.								
214						- ·								
215				<u>Yes</u>	<u>No</u>	<u>Excused</u>								
216			Robert Dimauro	X		Y.								
217			Patricia Edwards, MD	V		X								
218				Х										
219		Michelle Heaton X (exited meeting at 9:30 a.m.)												
220						X (exited meeting at 9:30 a.m.)								
221			Michelle Heaton Jerry Knirk, MD	x										
222			Michelle Heaton Jerry Knirk, MD Jason Margus	x		X (exited meeting at 9:30 a.m.) X (exited meeting at 9:58 a.m.)								
222			Michelle Heaton Jerry Knirk, MD Jason Margus Anne Marie Mercuri			X (exited meeting at 9:58 a.m.)								
223			Michelle Heaton Jerry Knirk, MD Jason Margus Anne Marie Mercuri Edward Moran	X X										
			Michelle Heaton Jerry Knirk, MD Jason Margus Anne Marie Mercuri	x		X (exited meeting at 9:58 a.m.)								

<sup>1</sup>Note: Per the "Board Chair Statement re: Public Commentary During Meetings", the Public Comment portion of the agenda is not an interactive session with the Board and comments must be germane to the business of the NHVA. Any questions should be directed to the NHVA's Executive Director who will respond in a timely fashion.



#### 227 Board of Directors – Executive Session Minutes

228

241

229 Ms. Tenney explained that the purpose of the executive session was to describe the results of her negotiations with 230 Helms and Company regarding the renewal of its executive director and assessment administrator contract, as 231 directed by the Board at its June 2024 meeting. She then described the fundamental terms of the proposed contract 232 renewal: an additional 5-year term with subsequent annual evergreen renewals (similar to the current contract) with 233 a fee increase that was higher in the first year than previous annual fee increases under the Helms contract, but 234 which fee would remain fixed over the five-year period. She explained that the fixed fee approach resulted in an 235 aggregate payment over the term that was less than the application of historic fee increases to each year in the 236 renewal term. 237

The Board asked questions and concurred that the terms negotiated by Ms. Tenney were reasonable and beneficial to the Association. Because a quorum was not present, the proposed amendment will be presented to the full Board at a later date for approval.

242 **VOTE RECORDED:** On a motion by Dr. Knirk, seconded by Mr. Fournier, by roll call it was unanimously 243 **VOTED:** To end the Executive Session at 10:20 a.m. 244 245 Excused Yes No 246 Robert Dimauro X 247 Patricia Edwards, MD Х 248 Marc Fournier Х 249 Michelle Heaton X (exited meeting at 9:30 a.m.) 250 Jerry Knirk, MD Х 251 X (exited meeting at 9:58 a.m.) Jason Margus 252 Anne Marie Mercuri X 253 Edward Moran Х 254 Х Susan Tenney 255 Wendy Wright, DNP Х 256 257 The executive session concluded at 10:20 a.m. 258 259 Executive Session meeting minutes submitted by: 260 Mark McCue, Esq. 261 NHVA External Counsel 262 September 19, 2024 263 264 8. Meeting Adjournment 265 266 **VOTE RECORDED:** On a motion by Mr. Fournier, seconded by Dr. Knirk, by roll call it was unanimously 267 **VOTED:** To move to adjourn the meeting at 10:22 a.m. 268 269 No Excused Yes 270 Robert Dimauro Х 271 Patricia Edwards. MD Х 272 Marc Fournier Х 273 Michelle Heaton X (exited meeting at 9:30 a.m.) 274 Jerry Knirk, MD Х 275 X (exited meeting at 9:58 a.m.) Jason Margus 276 Anne Marie Mercuri Х



277 278		Edward Moran		x		X
278		Susan Tenney Wendy Wright, DNP		^		X
280		wendy wright, Dive				^
280	Board of Directors Meetir	ng minutes respectfull	vsuh	nitted by		
282	Patrick Miller, Executive D		y 3001	inticu by		
283	September 26, 2024	nector				
284	September 20, 2024		#	#	#	
285			π	π	π	
200						

# **NHVA** New Hampshire Vaccine Association

# FY2024 Annual Report

#### Dear Supporter,

The NH Vaccine Association (NHVA) has had another active year. As of June 30, 2024, there were 212 provider sites enrolled in the NH Immunization Program (NHIP) providing immunizations to New Hampshire children and 95 payers remitting assessments to the NHVA to fund the immunizations. The total assessed child lives have rebounded slightly as the state emerged from the postpandemic period.

We are most appreciative of those who support the NHVA's mission to provide funding for childhood immunizations including our assessed payers, the NH Insurance Department (NHID), and the NH Department of Health and Human Services (NH DHHS).

Highlights from FY2024 include:

- Operating expenses as a percentage of total assessment income remained less than one percent at 0.84%.
- By having NH DHHS leverage the US Centers for Disease Control and Prevention's (CDC) Vaccine Price List, the NHVA's payers benefitted from a 29.9% discount on vaccine costs.
- The NH General Court updated the NHVA's governing statute to enable the funding for a monoclonal antibody for prevention and treatment of respiratory syncytial virus (RSV) in infants and toddlers.
- The NH DHHS and the NHVA continued to work closely together to anticipate future vaccine costs.

The NHVA would like to thank all its stakeholders for the ongoing success!

Susan M Jenney Susan M. Tenney

**Board Chair** 

(ADL

#### Patrick B. Miller, MPH Executive Director

## **Universal Vaccine Purchasing Program Overview and Benefits**

Universal vaccine purchasing programs allow a state to purchase all recommended vaccines for children, regardless of insurance coverage. New Hampshire's program enables state purchase of vaccines for every resident child and distribution of these vaccines to health care providers at no cost to them. The New Hampshire Vaccine Association (NHVA) employs a united approach involving commercial payers, providers, the NH Department of Health & Human Services, and the NH Insurance Department. For FY2024, 40% of the program funding was comprised of Federal Vaccine For Children Program (VFC) and State funds while the remaining 60% was comprised of commercial payer funds.

New Hampshire's Universal Purchase Program ensures that every child who enters a doctor's office, clinic, or hospital can receive recommended vaccines at no cost. More providers have been able to offer vaccination services because they are no longer required to finance the up-front costs of vaccines or be burdened with complex ordering systems. As a result, New Hampshire has one of the highest vaccination rates in the country, and consistently achieves higher vaccination rates than the U.S. as a whole. The program allows vaccines to be purchased from the U.S. Centers for Disease Control and Prevention which saves insurers and TPAs nearly 30% as the vaccines are not purchased on the open market.

**Financials Summary** 

Q

**ASI** 

Z

 $\mathbf{Y}$ 

COMPAR

SHEET

BALANCE

- Operating expenses as a percentage of total assessment income were 0.84% as of FYE June 30, 2024 versus 0.97% as of FYE June 30, 2023.
- Investment income is higher than the prior year due to increased fixed income rates and realized gains.

	<u>June 30, 202</u> 4	<u>I June 30, 2023</u>
Assessment Income, Interest on Late Assessments & TRICARE Settlement	\$18,310,143	\$13,873,987
Assets Released for Operations	(\$154,116)	(\$134,675)
Assets Released for Operations Operating Expenses as a % of Total Assessment Income	0.84%	0.97%
Bank & Sweep Interest & Return on Investments (Realized Gain o Loss)	<sup>r</sup> \$693,687	\$321,595
Remittance to State of New Hampshire	(\$19,600,000)	(\$17,850,929)
	June 30, 202	4 June 30,2023
ASSETS		
Current Assets		
Cash & Cash Equivalents	\$1,601,553	\$2,293,531
Cash & Cash Equivalents Accounts Receivable Prepaid Expenses Total Current Assets Total, Non-Current Assets Investments	\$-	\$-
Prepaid Expenses	\$1,960	\$1,960
Total Current Assets	\$1,603,513	\$2,295,431
Total, Non-Current Assets Investments	\$4,424,734	\$4,481,859
TOTAL ASSE	TS <u>\$6,028,247</u>	<u>\$6,777,350</u>
TOTAL ASSE LIABILITIES & NET ASSETS		
Current Liabilities		
A/P, Accrued Expenses, Refundable Overpayments TOTAL CURRENT LIABILITINN Net Assets	\$80	\$-
TOTAL CURRENT LIABILITI	ES \$80	\$-
Net Assets		
Net Assets without Donor Restrictions	\$250,000	\$250,000
Net Assets with Donor Restrictions	<u>\$5,778,167</u>	<u>\$6,527,350</u>
TOTAL NET ASSE	- +-,,	
TOTAL LIABILITIES & NET ASSE	TS <u>\$6,028,167</u>	

Meeting Packet Page 10





# A Message from the NH Department of Health and Human Services' Division of Public Health Services

This year marks the 30th anniversary of the launch of the Federal Vaccines for Children (VFC) Program, which was a historic step in improving children's lives by providing recommended vaccines at no cost. For 30 years, the program has served VFC eligible children who are uninsured, Medicaid-eligible or Medicaid-enrolled, American India an or Alaska Native, or underinsured. This national milestone also gives us a chance to pause and appreciate the successful collaboration between NHVA, DPHS, health insurers, and healthcare providers across the state to implement the New Hampshire universal vaccine purchase program for children which builds upon the VFC Program to provide no-cost immunizations to all individuals under 19 years of age regardless of insurance status. Our cooperative approach to funding New Hampshire's universal vaccines program for children has proven to be cost-effective and critical to our shared goal of reducing vaccine-preventable diseases.


#### Preventing Respiratory Syncytial Virus (RSV) in Infants

Last year, two options became available to parents for the prevention of severe RSV disease: the immunization *nirsevimab*, given to newborns and infants, and the *Abrysvo* vaccine, given during pregnancy to protect newborns. Thanks to recent legislation and passage of Senate Bill 559, which allows for the inclusion of nirsevimab in New Hampshire's universal vaccine purchase program for children, access to RSV protection has expanded. Both options are now available at no cost to individuals under 19 years of age, regardless of income or insurance status. For more information about immunizations to protect infants see <u>https://www.cdc.gov/rsv/vaccines/protect-infants.html</u>.

#### Vaccination Coverage Among NH Children

Thanks to New Hampshire's universal approach, the state has taken a critical step to ensure "community immunity" for protection against the threat of vaccine-preventable outbreaks.

According to the National Immunization Survey-Child, 2021-2023, the nation saw an overall decline in vaccination rates among children 24 months of age (born in 2020-2021). However, New England had the highest coverage of any region in the US with New Hampshire leading the way. Below, are highlighted regional coverage of the DTaP, polio, and MMR vaccines.




## Estimated Childhood Vaccine Coverage, Age 24 Months New England, 2021-2023

Data Source: NH Communicable Disease Report, National Immunization Survey-Child, United States, 2021–2023

# WWW.NHVACCINE.ORG

# **NHVA** New Hampshire Vaccine Association

For the 2023-2024 school year, vaccination coverage among New Hampshire children ages 19-59 months who were enrolled in childcare ranged from 92.6% for the measles, mumps, rubella vaccine (MMR) and varicella (chicken pox) to 95.1% for the Hepatitis B and Haemophilus influenzae type b vaccines.



We thank you for the work that you do, and we look forward to our continued efforts to preserve New Hampshire's high vaccination coverage and to help safeguard the

lain Watt Director. Division of Public Health Services

AM Collee m

Colleen Smith, MS Bureau Chief, Bureau of Infectious Disease Control

ame Marie Mercuri

Anne Marie Mercuri, BSN, MPH Chief. NH Immunization Section

# **NHVA Board of Directors**

**Governmental Representatives** Anne Marie Mercuri, BSN, MPH, Chief, Immunization Section, NH DHHS

**Michele Heaton, JD** Health Law and Policy Legal Counsel, NH Insurance Department

#### Healthcare Provider Representatives

Patricia M. Edwards, MD **Concord Pediatrics** Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP Wright & Associates Family Healthcare

#### **Insurer Representatives**

Jason Margus, FSA, MAAA Director of Actuary Anthem Blue Cross and Blue Shield Susan Tenney Director, Network Contracting Harvard Pilgrim Health Care, Inc. Morgan Brown Senior Contract Manager Cigna Healthcare

#### **Public Members**

**Edward P. Moran** Appointed by the Speaker of the House Lorraine Radick Appointed by the President of the Senate

# **Representatives of Self-Insured** Entities

Marc Fournier, Dir. Human Resources University System of New Hampshire Appointed by the Governor and Council

WWW.NHVACCINE.ORG



# Helms & Company, Inc. Staff

603-225-6633 603-225-4739

Patrick B. Miller. MPH Executive Director, NHVA

Erin K. Meagher Office Manager

Administrator

Phone:

Fax:

Keith R. Nix Controller



OMPANY

# WWW.NHVACCINE.ORG

### Meeting Packet Page 12

# NHVA UNAUDITED Statement of Cash Flow Month Ended October 31, 2024

			FY25 - Q1 Actual	1	FY25 - Q2 Actual		FY25 - Q3 Actual		FY25 - Q4 Actual		FY 2025 'TD Actual	FY 2025 YTD Budget		Difference YTD Act to Budget		FY 2025 Annual Budget	
Receip	ots (Source)																
	Assessment Income	\$	6,056,488	\$	889,350	\$	-	\$	-	\$	6,945,838	\$	7,120,199	\$	(174,362)	\$	24,220,500
*	Accounts Receivable	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-
	Interest Income - Assessments	\$	613	\$	-	\$	-	\$	-	\$	613	\$	763	\$	(150)	\$	1,103
	Interest Income - Bank & Sweep (ICS)	\$	62,283	\$	31,497	\$	-	\$	-	\$	93,779	\$	83,290	\$	10,489	\$	516,071
	Interest Income - Investments	\$	13,259	\$	6,627	\$	-	\$	-	\$	19,886	\$	20,748	\$	(862)	\$	65,005
	Dividend Income	\$	3,052	\$	941	\$	-	\$	-	\$	3,994	\$	3,882	\$	112	\$	13,495
	Accrued Investment Income	\$	1,815	\$	(1,575)	\$	-	\$	-	\$	240	\$	25	\$	215	\$	(544)
	Investment Advisory fees	\$	(4,208)	\$	(1,418)	\$	-	\$	-	\$	(5,625)	\$	(5 <i>,</i> 745)	\$	120	\$	(17,199)
	Realized Gain or Loss	\$	741	\$	-	\$	-	\$	-	\$	741	\$	17	\$	724	\$	14
	Unrecognized Gain or Loss	\$	94,354	\$	3,232	\$	-	\$	-	\$	97,585	\$	8,246	\$	89,339	\$	116,845
**	Investment - Short term, CDs and Accrual.	\$	(79,012)	\$	(7,808)	\$	-	\$	-	\$	(86,820)	\$	-	\$	(86,820)	\$	-
		\$	6,149,384	\$	920,847	\$	-	\$	-	\$	7,070,230	\$	7,231,426	\$	(161,196)	\$	24,915,290
Disbu	rsements (Use)																
***	Expenses	\$	39,430	\$	15,326	\$	-	\$	-	\$	54,757	\$	1,310	\$	53,447	\$	159,912
*	Prepaids & Accrual Changes	\$	(761)	\$	(730)	\$	-	\$	-	\$	(1,491)	\$	-	\$	(1,491)	\$	-
	Vaccine Expenses	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	23,760,041
		\$	38,670	\$	14,596	\$	-	\$	-	\$	53,266	\$	1,310	\$	51,956	\$	23,919,953
	Increase (Decrease)	\$	6,110,714	\$	906,250	\$	-	\$	-	\$	7,016,964	\$	7,230,116	\$	(213,152)	\$	995,337
	Cash Balance - Beginning Cash Balance - Ending	\$ \$	1,601,553 7,712,266	\$ \$	7,712,266 8,618,517	\$ \$	8,618,517 8,618,517	\$ \$	8,618,517 8,618,517	\$ \$	1,601,553 8,618,517	\$ \$	1,601,553 8,831,668	\$ \$	- (213,152)	\$ \$	1,601,553 2,596,890

#### Notes:

\* Changes in Balance Sheet accounts are denoted as () = Increases and positive = decrease

\*\* A positive number represents amounts transferred to the ICS account from the Short Term Investments (CDs) account A negative number represents amounts transferred to the Short Term Investemts (CDs) account from the ICS account

\*\*\* Budgeted expense includes annual State of NH payment due June 2025

# NHVA UNAUDITED Statement of Financial Position YTD FY2025 Q2

Month Ended October 31, 2024

		Jun 30, 24		Sep 30, 24	Oct 31, 24	Mar	31, 25	Jun	30, 25
ASSETS		FYE 24		FY25 - Q1	FY25 - Q2	FY2	5 - Q3	FY2	5 - Q4
Current Assets		Audited		Interim	Interim				
Checking/Savings									
Bank of NH #851031104	\$	46,500	\$	46,500	\$ 50,000	\$	-	\$	-
Bank of NH - ICS	\$	1,555,053	\$	7,665,766	\$ 8,568,517	\$	-	\$	-
Total Checking/Savings	\$	1,601,553	\$	7,712,266	\$ 8,618,517	\$	-	\$	-
Accounts Receivable									
Accounts Receivable (A/R)	\$	-	\$	-	\$ -	\$	-	\$	-
Allowance for Account Receivable	\$	-	\$	-	\$ -	\$	-	\$	-
Total Accounts Receivable	\$	-	\$	-	\$ -	\$	-	\$	-
Other Current Assets									
Prepaid Expenses	\$	1,960	\$	1,120	\$ 840	\$	-	\$	-
Short Term Investments :									
Short Term Investment - FMV	\$	4,419,083	\$	4,496,281	\$ 4,505,663	\$	-	\$	-
Accrued Investment Income	\$	5,651	\$	7,466	\$ 5,891	\$	-	\$	-
Total Short Term Investments	\$	4,424,734	\$	4,503,747	\$ 4,511,554	\$	-	\$	-
Total Other Current Assets	\$	4,426,694	\$	4,504,867	\$ 4,512,394	\$	-	\$	-
Total Current Assets	\$	6,028,247	\$	12,217,133	\$ 13,130,911	\$	-	\$	-
TOTAL ASSETS	\$	6,028,247	\$	12,217,133	\$ 13,130,911	\$	-	\$	-
LIABILITIES & EQUITY					 				
Liabilities									
Current Liabilities									
* Accrued Expenses & Deferred Revenue	\$	80	\$	-	\$ 450	\$	-	\$	-
Other Current Liabilities									
Liquidity Reserve	\$	250,000	\$	250,000	\$ 250,000	\$	-	\$	-
Total Current Liabilities	\$	250,080	\$	250,000	\$ 250,450	\$	-	\$	-
Total Liabilities	\$	250,080	\$	250,000	\$ 250,450	\$	-	\$	-
Equity									
Retained Earnings	\$	4,681,322	\$	3,932,139	\$ 3,932,139	\$	-	\$	-
Fund Balance to be Distributed	\$	1,846,029	\$	1,846,029	\$ 1,846,029	\$	-	\$	-
Net Income	\$	(749,183)	\$	6,188,966	\$ 7,102,294	\$	-	\$	-
Total Equity	\$	5,778,167	\$	11,967,133	\$ 12,880,461	\$	-	\$	-
TOTAL LIABILITIES & EQUITY	\$	6,028,247	\$	12,217,133	\$ 13,130,911	\$	-	\$	-

Notes\* AP State of New Hampshire Payable (June 2025)

Estimate

23,760,041

## NHVA UNAUDITED Statement of Changes in Net Assets YTD FY2025 Q2 Month Ended October 31, 2024

			_													
		FY25 - Q1	F	Y25 - Q2	FY	′25 - Q3	FY	′25 - Q4		FY 2025		FY 2025	D	ifference		FY 2025
		Actual		Actual	/	Actual	ļ	Actual	١	TD Actual	Y	TD Budget	YTD	Act to Bud	A	nnual Budget
Ordinary Income/Expense	Interim Interim		Interim						Interim							
Income																
Assessment Income	\$	6,056,488	\$	889,350	\$	-	\$	-	\$	6,945,838	\$	7,120,199	\$	(174,362)	\$	24,220,500
Interest Income - Assessments	\$	613	\$	-	\$	-	\$	-	\$	613	\$	763	\$	(150)	\$	1,103
Interest Income - Bank & Sweep (ICS)	\$	62,283	\$	31,497	\$	-	\$	-	\$	93,779	\$	83,290	\$	10,489	\$	516,071
Return on Investments :																
Interest Income - Investments	\$	13,259	\$	6,627	\$	-	\$	-	\$	19,886	\$	20,748	\$	(862)	\$	65,005
Dividend Income	\$	3,052	\$	941	\$	-	\$	-	\$	3,994	\$	3,882	\$	112	\$	13,495
Accrued Investment Inc Earned	\$	1,815	\$	(1,575)	\$	-	\$	-	\$	240	\$	25	\$	215	\$	(544)
Investment Advisory fees	\$	(4,208)	\$	(1,418)	\$	-	\$	-	\$	(5,625)	\$	(5,745)	\$	120	\$	(17,199)
Realized Gain or Loss	\$	741	\$	-	\$	-	\$	-	\$	741	\$	17	\$	724	\$	14
Unrecognized Gain or Loss	\$	94,354	\$	3,232	\$	-	\$	-	\$	97,585	\$	8,246	\$	89,339	\$	116,845
Total Return on Investments :	\$	109,012	\$	7,808	\$	-	\$	-	\$	116,820	\$	27,174	\$	89,646	\$	177,616
Total Income	\$	6,228,396	\$	928,654	\$	-	\$	-	\$	7,157,050	\$	7,231,426	\$	(74,376)	\$	24,915,290
Expenses																
Vaccine - Annual State Payment	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	23,760,041
Management Fees	\$	28,749	\$	9,583	\$	-	\$	-	\$	38,332	\$	38,616	\$	(284)	\$	117,552
Professional Fees																
Professional Fees - Legal	\$	2,783	\$	3,630	\$	-	\$	-	\$	6,413	\$	8,333	\$	(1,921)	\$	25,000
Professional Fees - Audit	\$	7,000	\$	-	\$	-	\$	-	\$	7,000	\$	6,785	\$	215	\$	10,285
Total · Professional Fees	\$	9,783	\$	3,630	\$	-	\$	-	\$	13,413	\$	15,118	\$	(1,706)	\$	35,285
Insurance	\$	840	\$	280	\$	-	\$	-	\$	1,120	\$	1,417	\$	(297)	\$	4,250
Postage & Printing (Office)	\$	59	\$	42	\$	-	\$	-	\$	101	\$	180	\$	(79)	\$	540
Licenses and Fees	\$	-	\$	75	\$	-	\$	-	\$	75	\$	75	\$	-	\$	75
Bank Service Charges	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-
Website & SubContractors	\$	-	\$	486	\$	-	\$	-	\$	486	\$	525	\$	(39)	\$	525
Board Meetings Expense	\$	-	\$	1,230	\$	-	\$	-	\$	1,230	\$	1,110	\$	120	\$	1,685
Total Expenses	\$	39,430	\$	15,326	\$	-	\$	-	\$	54,757	\$	57,041	\$	(2,284)	\$	23,919,953
Net Ordinary Income	\$	6,188,966	\$	913,328	\$	-	\$	-	\$	7,102,294	\$	7,174,385	\$	(72,091)	\$	995,337
Net Income	\$	6,188,966	\$	913,328	\$	-	\$	-	\$	7,102,294	\$	7,174,385	\$	(72,091)	\$	995,337
Collection Data:																
Quarter being collected	_	6FY24 - Q4	-	FY25 - Q1		Y25 - Q2		Y25 - Q3		SFY25						
Payment Due Date		08/15/24	1	1/15/24	02	2/15/25	05	5/15/25	Ì	Y-T-D Lives						
Projected Average Monthly Lives		160,667		53,556		-		-	214,223							
Actual Average Monthly Lives		161,506		69,317		-		-		230,823						
Avg Lives Variance +(-)		839		15,761		-		-		16,600						
Approved Assessment Rate	\$	12.50	\$	12.50	\$	12.50	\$	12.75								